KRAS: Old Target, New Hope

IMpower010: Adjuvant Atezolizumab Improved DFS in PD-L1 Expressing Stage II-IIIA NSCLC

Molecular Resistance Mechanisms to EGFR, ALK, and ROS1 TKIs

Approval of Combination Ipilimumab and Nivolumab for Mesothelioma: What Happens Now?

Leveraging Lung Cancer Screening Scans to Detect Early Interstitial and Obstructive Lung Disease

Low-Dose CT Screening with Guidance from Biomarkers May be Beneficial for Some Patients Who Have Never Smoked

Strategies for Implementing Lung Cancer Screening Programs in Low-Middle Income Countries

Low-Dose CT Could be One-Stop Test for Early Signs of China’s ‘Big Three’ Chest Diseases

The 50-year Journey to Optimize Lung Cancer Screening Programs

Optimizing CT Performance Through Use of Tumor Phantoms

Prolonging CT Screening Intervals is Deemed Safe in Individuals with Negative Baseline Results

A National Network Provides a Window into Lung Cancer Screening Trends, Successes across the United States